Aldeyra director granted stock options at $1.72

Director Nancy Miller-Rich received two stock option awards from Aldeyra Therapeutics, Inc. These options allow her to buy 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share, with an expiration date of June 8, 2036.

Rhea-AI Filing Summary

Director Nancy Miller-Rich received two stock option awards from Aldeyra Therapeutics, Inc. These options allow her to buy 3,318 and 70,000 shares of common stock at an exercise price of $1.72 per share, with an expiration date of June 8, 2036.

Each option becomes exercisable with respect to 100% of the shares on the one-year anniversary of the grant date. Vesting is conditioned on her continued service on the Board of Directors and, for the larger grant, on the Compensation Committee through the applicable vesting date. These are compensation-related grants, not open-market purchases or sales.

Insider Trade Summary

Grant/Award: 73,318 shares

Grant/Award 2 txns

Insider Miller-Rich Nancy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	3,318	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 73,318 contracts (Direct)

Footnotes (2)

1. F1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
2. F2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.

Key Figures

Option grant (Board service): 3,318 shares at $1.72/share Option grant (Comp Committee): 70,000 shares at $1.72/share Expiration date: June 8, 2036 +1 more

4 metrics

Option grant (Board service) 3,318 shares at $1.72/share Stock Option (Right to Buy), expiration June 8, 2036

Option grant (Comp Committee) 70,000 shares at $1.72/share Stock Option (Right to Buy), expiration June 8, 2036

Expiration date June 8, 2036 Both option grants reported on Form 4

Vesting schedule 100% after one year Requires continuous Board or Committee service to vest

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Compensation Committee, continuous service

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Compensation Committee financial

"service as a member of the Compensation Committee of the Board of Directors"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

continuous service financial

"provided that the Reporting Person provides continuous service as a member of the Board"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aldeyra Therapeutics (ALDX) report for Nancy Miller-Rich?

Aldeyra Therapeutics reported that director Nancy Miller-Rich received two stock option grants. The awards cover 3,318 and 70,000 underlying common shares, providing future purchase rights as part of her equity compensation for board and committee service.

How many Aldeyra Therapeutics (ALDX) shares are covered by the new stock options?

The new stock options cover 3,318 shares and 70,000 shares of Aldeyra common stock. These options give the director the right to buy those shares in the future if vesting and other conditions are satisfied.

What is the exercise price of Nancy Miller-Rich’s Aldeyra (ALDX) stock options?

Both stock option grants to director Nancy Miller-Rich have an exercise price of $1.72 per share. This is the fixed price at which she can purchase Aldeyra common stock once the options vest and she chooses to exercise them.

When do the new Aldeyra Therapeutics (ALDX) stock options expire?

The reported stock options expire on June 8, 2036. After that expiration date, any unexercised options will lapse, and the right to purchase Aldeyra common shares at the $1.72 strike price will no longer be available.

What are the vesting conditions for the Aldeyra (ALDX) options granted to Nancy Miller-Rich?

Each grant vests 100% on the one-year anniversary of the grant date. Vesting requires that Ms. Miller-Rich continues to serve on the Board, and for one grant, on the Compensation Committee, through the relevant vesting date.

Are Nancy Miller-Rich’s Aldeyra (ALDX) option grants open-market share purchases?

No. The Form 4 describes these as grant, award, or other acquisition transactions. They are stock option awards issued as compensation, not open-market purchases or sales of Aldeyra common stock by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller-Rich Nancy

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.72	06/09/2026		A		70,000		(1)	06/08/2036	Common Stock	70,000	$0	70,000	D
Stock Option (Right to Buy)	$1.72	06/09/2026		A		3,318		(2)	06/08/2036	Common Stock	3,318	$0	3,318	D

Explanation of Responses:

1. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.

2. Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.

	/s/ Nancy Miller-Rich	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)